LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article ; Online: Leveraging pleiotropic association using sparse group variable selection in genomics data

    Matthew Sutton / Pierre-Emmanuel Sugier / Therese Truong / Benoit Liquet

    BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-

    2022  Volume 12

    Abstract: Abstract Background Genome-wide association studies (GWAS) have identified genetic variants associated with multiple complex diseases. We can leverage this phenomenon, known as pleiotropy, to integrate multiple data sources in a joint analysis. Often ... ...

    Abstract Abstract Background Genome-wide association studies (GWAS) have identified genetic variants associated with multiple complex diseases. We can leverage this phenomenon, known as pleiotropy, to integrate multiple data sources in a joint analysis. Often integrating additional information such as gene pathway knowledge can improve statistical efficiency and biological interpretation. In this article, we propose statistical methods which incorporate both gene pathway and pleiotropy knowledge to increase statistical power and identify important risk variants affecting multiple traits. Methods We propose novel feature selection methods for the group variable selection in multi-task regression problem. We develop penalised likelihood methods exploiting different penalties to induce structured sparsity at a gene (or pathway) and SNP level across all studies. We implement an alternating direction method of multipliers (ADMM) algorithm for our penalised regression methods. The performance of our approaches are compared to a subset based meta analysis approach on simulated data sets. A bootstrap sampling strategy is provided to explore the stability of the penalised methods. Results Our methods are applied to identify potential pleiotropy in an application considering the joint analysis of thyroid and breast cancers. The methods were able to detect eleven potential pleiotropic SNPs and six pathways. A simulation study found that our method was able to detect more true signals than a popular competing method while retaining a similar false discovery rate. Conclusion We developed feature selection methods for jointly analysing multiple logistic regression tasks where prior grouping knowledge is available. Our method performed well on both simulation studies and when applied to a real data analysis of multiple cancers.
    Keywords Genetic epidemiology ; High dimensional data ; Lasso penalization ; Oncology ; Pathway analysis ; Pleiotropy ; Medicine (General) ; R5-920
    Subject code 310
    Language English
    Publishing date 2022-01-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Penalized partial least squares for pleiotropy

    Camilo Broc / Therese Truong / Benoit Liquet

    BMC Bioinformatics, Vol 22, Iss 1, Pp 1-

    2021  Volume 31

    Abstract: Abstract Background The increasing number of genome-wide association studies (GWAS) has revealed several loci that are associated to multiple distinct phenotypes, suggesting the existence of pleiotropic effects. Highlighting these cross-phenotype genetic ...

    Abstract Abstract Background The increasing number of genome-wide association studies (GWAS) has revealed several loci that are associated to multiple distinct phenotypes, suggesting the existence of pleiotropic effects. Highlighting these cross-phenotype genetic associations could help to identify and understand common biological mechanisms underlying some diseases. Common approaches test the association between genetic variants and multiple traits at the SNP level. In this paper, we propose a novel gene- and a pathway-level approach in the case where several independent GWAS on independent traits are available. The method is based on a generalization of the sparse group Partial Least Squares (sgPLS) to take into account groups of variables, and a Lasso penalization that links all independent data sets. This method, called joint-sgPLS, is able to convincingly detect signal at the variable level and at the group level. Results Our method has the advantage to propose a global readable model while coping with the architecture of data. It can outperform traditional methods and provides a wider insight in terms of a priori information. We compared the performance of the proposed method to other benchmark methods on simulated data and gave an example of application on real data with the aim to highlight common susceptibility variants to breast and thyroid cancers. Conclusion The joint-sgPLS shows interesting properties for detecting a signal. As an extension of the PLS, the method is suited for data with a large number of variables. The choice of Lasso penalization copes with architectures of groups of variables and observations sets. Furthermore, although the method has been applied to a genetic study, its formulation is adapted to any data with high number of variables and an exposed a priori architecture in other application fields.
    Keywords Genetic epidemiology ; High dimensional data ; Lasso Penalization ; Meta-analysis ; Oncology ; Partial Least Square ; Computer applications to medicine. Medical informatics ; R858-859.7 ; Biology (General) ; QH301-705.5
    Subject code 519
    Language English
    Publishing date 2021-02-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Role of GSTM1 and GSTT1 genotypes in differentiated thyroid cancer and interaction with lifestyle factors

    Catherine Tcheandjieu / Emilie Cordina-Duverger / Claire Mulot / Dominique Baron-Dubourdieu / Anne-Valérie Guizard / Claire Schvartz / Pierre Laurent-Puig / Pascal Guénel / Thérèse Truong

    PLoS ONE, Vol 15, Iss 1, p e

    Results from case-control studies in France and New Caledonia.

    2020  Volume 0228187

    Abstract: BACKGROUND:GSTM1 and GSTT1 are involved in detoxification of xenobiotics, products of oxidative stress and in steroid hormones metabolism. We investigated whether GSTM1 and GSTT1 gene deletion was associated with DTC risk and explored interaction with ... ...

    Abstract BACKGROUND:GSTM1 and GSTT1 are involved in detoxification of xenobiotics, products of oxidative stress and in steroid hormones metabolism. We investigated whether GSTM1 and GSTT1 gene deletion was associated with DTC risk and explored interaction with non-genetic risk factors of DTC. METHODS:The study included 661 DTC cases and 736 controls from two case-control studies conducted in France and New Caledonia. Odds ratios (OR) and their confidence interval (CI) for DTC associated with GST genotypes, alcohol drinking, tobacco smoking, body mass index and hormonal factors were calculated using logistic regression models. RESULTS:Results are presented for Europeans and Melanesians combined, as no heterogeneity between groups was detected. We found that DTC risk increased with obesity and decrease with alcohol drinking. After stratification by gene deletion status, the OR for obesity was 5.75, (95%CI 2.25-14.7) among individuals with GSTT1 and GSTM1-deleted genotype, and 1.26, (95%CI 0.89-1.77) in carriers of both genes (p-interaction = 0.02). The OR for drinking ≥1 glass/week was 0.33 (95%CI 0.15-0.74) in GSTT1-null individuals while it was 1.01 (95%CI 0.67-1.52) in non-null carriers of the gene (p-interaction = 0.01). No interaction between GST genotypes and other non-genetic risk factors was detected. CONCLUSION:GSTM1 and GSTT1 genotypes may modulate the DTC risk associated with BMI and alcohol consumption.
    Keywords Medicine ; R ; Science ; Q
    Subject code 610
    Language English
    Publishing date 2020-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Association of Mediterranean diet with survival after breast cancer diagnosis in women from nine European countries

    Carlota Castro-Espin / Catalina Bonet / Marta Crous-Bou / Núria Nadal-Zaragoza / Anne Tjønneland / Lene Mellemkjær / Mariem Hajji-Louati / Thérèse Truong / Verena Katzke / Charlotte Le Cornet / Matthias B. Schulze / Franziska Jannasch / Giovanna Masala / Sabina Sieri / Salvatore Panico / Chiara Di Girolamo / Guri Skeie / Kristin Benjaminsen Borch / Karina Standahl Olsen /
    Maria-Jose Sánchez / Pilar Amiano / María-Dolores Chirlaque / Marcela Guevara / Malin Sund / Stina Bodén / Marc J. Gunter / Esther M. Gonzalez-Gil / Elisabete Weiderpass / Inmaculada Aguilera-Buenosvinos / Kostas K. Tsilidis / Alicia K. Heath / Dagfinn Aune / Laure Dossus / Antonio Agudo

    BMC Medicine, Vol 21, Iss 1, Pp 1-

    results from the EPIC cohort study

    2023  Volume 11

    Abstract: Abstract Background The Mediterranean diet has been associated with lower risk of breast cancer (BC) but evidence from prospective studies on the role of Mediterranean diet on BC survival remains sparse and conflicting. We aimed to investigate whether ... ...

    Abstract Abstract Background The Mediterranean diet has been associated with lower risk of breast cancer (BC) but evidence from prospective studies on the role of Mediterranean diet on BC survival remains sparse and conflicting. We aimed to investigate whether adherence to Mediterranean diet prior to diagnosis is associated with overall and BC-specific mortality. Methods A total of 13,270 incident breast cancer cases were identified from an initial sample of 318,686 women in 9 countries from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Adherence to Mediterranean diet was estimated through the adapted relative Mediterranean diet (arMED), a 16-point score that includes 8 key components of the Mediterranean diet and excludes alcohol. The degree of adherence to arMED was classified as low (score 0–5), medium (score 6–8), and high (score 9–16). Multivariable Cox proportional hazards models were used to analyze the association between the arMED score and overall mortality, and Fine-Gray competing risks models were applied for BC-specific mortality. Results After a mean follow-up of 8.6 years from diagnosis, 2340 women died, including 1475 from breast cancer. Among all BC survivors, low compared to medium adherence to arMED score was associated with a 13% higher risk of all-cause mortality (HR 1.13, 95%CI 1.01–1.26). High compared to medium adherence to arMED showed a non-statistically significant association (HR 0.94; 95% CI 0.84–1.05). With no statistically significant departures from linearity, on a continuous scale, a 3-unit increase in the arMED score was associated with an 8% reduced risk of overall mortality (HR3-unit 0.92, 95% CI: 0.87–0.97). This result sustained when restricted to postmenopausal women and was stronger among metastatic BC cases (HR3-unit 0.81, 95% CI: 0.72–0.91). Conclusions Consuming a Mediterranean diet before BC diagnosis may improve long-term prognosis, particularly after menopause and in cases of metastatic breast cancer. Well-designed dietary interventions are ...
    Keywords Mediterranean diet ; Breast cancer ; Cancer survivors ; Dietary patterns ; Prospective studies ; Medicine ; R
    Subject code 610 ; 616
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Risk of breast cancer by type of menopausal hormone therapy

    Emilie Cordina-Duverger / Thérèse Truong / Antoinette Anger / Marie Sanchez / Patrick Arveux / Pierre Kerbrat / Pascal Guénel

    PLoS ONE, Vol 8, Iss 11, p e

    a case-control study among post-menopausal women in France.

    2013  Volume 78016

    Abstract: Background There is extensive epidemiological evidence that menopausal hormone therapy (MHT) increases breast cancer risk, particularly combinations of estrogen and progestagen (EP). We investigated the effects of the specific formulations and types of ... ...

    Abstract Background There is extensive epidemiological evidence that menopausal hormone therapy (MHT) increases breast cancer risk, particularly combinations of estrogen and progestagen (EP). We investigated the effects of the specific formulations and types of therapies used by French women. Progestagen constituents, regimen (continuous or sequential treatment by the progestagen), and time interval between onset of menopause and start of MHT were examined. Methods We conducted a population-based case-control study in France in 1555 menopausal women (739 cases and 816 controls). Detailed information on MHT use was obtained during in-person interviews. Odds ratios and 95% confidence interval adjusted for breast cancer risk factors were calculated. Results We found that breast cancer risk differed by type of progestagen among current users of EP therapies. No increased risk was apparent among EP therapy users treated with natural micronized progesterone. Among users of EP therapy containing a synthetic progestin, the odds ratio was 1.57 (0.99-2.49) for progesterone-derived and 3.35 (1.07-10.4) for testosterone-derived progestagen. Women with continuous regimen were at greater risk than women treated sequentially, but regimen and type of progestagen could not be investigated independently, as almost all EP combinations containing a testosterone-derivative were administered continuously and vice-versa. Tibolone was also associated with an increased risk of breast cancer. Early users of MHT after onset of menopause were at greater risk than users who delayed treatment. Conclusion This study confirms differential effects on breast cancer risk of progestagens and regimens specifically used in France. Formulation of EP therapies containing natural progesterone, frequently prescribed in France, was not associated with increased risk of breast cancer but may poorly protect against endometrial cancer.
    Keywords Medicine ; R ; Science ; Q
    Subject code 610 ; 616
    Language English
    Publishing date 2013-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Gene network and biological pathways associated with susceptibility to differentiated thyroid carcinoma

    Om Kulkarni / Pierre-Emmanuel Sugier / Julie Guibon / Anne Boland-Augé / Christine Lonjou / Delphine Bacq-Daian / Robert Olaso / Carole Rubino / Vincent Souchard / Frédérique Rachedi / Juan Jesus Lence-Anta / Rosa Maria Ortiz / Constance Xhaard / Pierre Laurent-Puig / Claire Mulot / Anne-Valérie Guizard / Claire Schvartz / Marie-Christine Boutron-Ruault / Evgenia Ostroumova /
    Ausrele Kesminiene / Jean-François Deleuze / Pascal Guénel / Florent De Vathaire / Thérèse Truong / Fabienne Lesueur

    Scientific Reports, Vol 11, Iss 1, Pp 1-

    2021  Volume 12

    Abstract: Abstract Variants identified in earlier genome-wide association studies (GWAS) on differentiated thyroid carcinoma (DTC) explain about 10% of the overall estimated genetic contribution and could not provide complete insights into biological mechanisms ... ...

    Abstract Abstract Variants identified in earlier genome-wide association studies (GWAS) on differentiated thyroid carcinoma (DTC) explain about 10% of the overall estimated genetic contribution and could not provide complete insights into biological mechanisms involved in DTC susceptibility. Integrating systems biology information from model organisms, genome-wide expression data from tumor and matched normal tissue and GWAS data could help identifying DTC-associated genes, and pathways or functional networks in which they are involved. We performed data mining of GWAS data of the EPITHYR consortium (1551 cases and 1957 controls) using various pathways and protein–protein interaction (PPI) annotation databases and gene expression data from The Cancer Genome Atlas. We identified eight DTC-associated genes at known loci 2q35 (DIRC3), 8p12 (NRG1), 9q22 (FOXE1, TRMO, HEMGN, ANP32B, NANS) and 14q13 (MBIP). Using the EW_dmGWAS approach we found that gene networks related to glycogenolysis, glycogen metabolism, insulin metabolism and signal transduction pathways associated with muscle contraction were overrepresented with association signals (false discovery rate adjusted p-value < 0.05). Additionally, suggestive association of 21 KEGG and 75 REACTOME pathways with DTC indicate a link between DTC susceptibility and functions related to metabolism of cholesterol, amino sugar and nucleotide sugar metabolism, steroid biosynthesis, and downregulation of ERBB2 signaling pathways. Together, our results provide novel insights into biological mechanisms contributing to DTC risk.
    Keywords Medicine ; R ; Science ; Q
    Subject code 570
    Language English
    Publishing date 2021-04-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women

    Xiaoliang Wang / Pooja Middha Kapoor / Paul L. Auer / Joe Dennis / Alison M. Dunning / Qin Wang / Michael Lush / Kyriaki Michailidou / Manjeet K. Bolla / Kristan J. Aronson / Rachel A. Murphy / Angela Brooks-Wilson / Derrick G. Lee / Emilie Cordina-Duverger / Pascal Guénel / Thérèse Truong / Claire Mulot / Lauren R. Teras / Alpa V. Patel /
    Laure Dossus / Rudolf Kaaks / Reiner Hoppe / Wing-Yee Lo / Thomas Brüning / Ute Hamann / Kamila Czene / Marike Gabrielson / Per Hall / Mikael Eriksson / Audrey Jung / Heiko Becher / Fergus J. Couch / Nicole L. Larson / Janet E. Olson / Kathryn J. Ruddy / Graham G. Giles / Robert J. MacInnis / Melissa C. Southey / Loic Le Marchand / Lynne R. Wilkens / Christopher A. Haiman / Håkan Olsson / Annelie Augustinsson / Ute Krüger / Philippe Wagner / Christopher Scott / Stacey J. Winham / Celine M. Vachon / Charles M. Perou / Andrew F. Olshan

    Scientific Reports, Vol 12, Iss 1, Pp 1-

    2022  Volume 12

    Abstract: Abstract Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis ... ...

    Abstract Abstract Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values < 5 × 10–8 as genome-wide significant, and p-values < 1 × 10–5 as suggestive. Linkage disequilibrium (LD)-based clumping was performed to identify independent candidate variants. None of the 9.7 million genetic variants tested for interactions with MHT use reached genome-wide significance. Only 213 variants, representing 18 independent loci, had p-values < 1 × 105. The strongest evidence was found for rs4674019 (p-value = 2.27 × 10–7), which showed genome-wide significant interaction (p-value = 3.8 × 10–8) with current MHT use when analysis was restricted to population-based studies only. Limiting the analyses to combined estrogen–progesterone MHT use only or to estrogen receptor (ER) positive cases did not identify any genome-wide significant evidence of interactions. In this large genome-wide SNP-MHT interaction study of breast cancer, we found no strong support for common genetic variants modifying the effect of MHT on breast cancer risk. These results suggest that common genetic variation has limited impact on the observed MHT–breast cancer risk association.
    Keywords Medicine ; R ; Science ; Q
    Subject code 616
    Language English
    Publishing date 2022-04-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: The association between genetically elevated polyunsaturated fatty acids and risk of cancerResearch in context

    Philip C. Haycock / Maria Carolina Borges / Kimberley Burrows / Rozenn N. Lemaitre / Stephen Burgess / Nikhil K. Khankari / Konstantinos K. Tsilidis / Tom R. Gaunt / Gibran Hemani / Jie Zheng / Therese Truong / Brenda M. Birmann / Tracy OMara / Amanda B. Spurdle / Mark M. Iles / Matthew H. Law / Susan L. Slager / Fatemeh Saberi Hosnijeh / Daniela Mariosa /
    Michelle Cotterchio / James R. Cerhan / Ulrike Peters / Stefan Enroth / Puya Gharahkhani / Loic Le Marchand / Ann C. Williams / Robert C. Block / Christopher I. Amos / Rayjean J. Hung / Wei Zheng / Marc J. Gunter / George Davey Smith / Caroline Relton / Richard M. Martin / Nathan Tintle / Terri Rice / Iona Cheng / Mark Jenkins / Steve Gallinger / Alex J. Cornish / Amit Sud / Jayaram Vijayakrishnan / Margaret Wrensch / Mattias Johansson / Aaron D. Norman / Alison Klein / Alyssa Clay-Gilmour / Andre Franke / Andres V. Ardisson Korat / Bill Wheeler / Björn Nilsson / Caren Smith / Chew-Kiat Heng / Ci Song / David Riadi / Elizabeth B. Claus / Eva Ellinghaus / Evgenia Ostroumova / Hosnijeh / Florent de Vathaire / Giovanni Cugliari / Giuseppe Matullo / Irene Oi-Lin Ng / Jeanette E. Passow / Jia Nee Foo / Jiali Han / Jianjun Liu / Jill Barnholtz-Sloan / Joellen M. Schildkraut / John Maris / Joseph L. Wiemels / Kari Hemminki / Keming Yang / Lambertus A. Kiemeney / Lang Wu / Laufey Amundadottir / Marc-Henri Stern / Marie-Christine Boutron / Mark Martin Iles / Mark P. Purdue / Martin Stanulla / Melissa Bondy / Mia Gaudet / Lenha Mobuchon / Nicola J. Camp / Pak Chung Sham / Pascal Guénel / Paul Brennan / Philip R. Taylor / Quinn Ostrom / Rachael Stolzenberg-Solomon / Rajkumar Dorajoo / Richard Houlston / Robert B. Jenkins / Sharon Diskin / Sonja I. Berndt / Spiridon Tsavachidis / Stephen J. Channock / Tabitha Harrison / Tessel Galesloot / Ulf Gyllensten / Vijai Joseph / Y. Shi / Wenjian Yang / Yi Lin / Stephen K. Van Den Eeden

    EBioMedicine, Vol 91, Iss , Pp 104510- (2023)

    2023  

    Abstract: Summary: Background: The causal relevance of polyunsaturated fatty acids (PUFAs) for risk of site-specific cancers remains uncertain. Methods: Using a Mendelian randomization (MR) framework, we assessed the causal relevance of PUFAs for risk of cancer in ...

    Abstract Summary: Background: The causal relevance of polyunsaturated fatty acids (PUFAs) for risk of site-specific cancers remains uncertain. Methods: Using a Mendelian randomization (MR) framework, we assessed the causal relevance of PUFAs for risk of cancer in European and East Asian ancestry individuals. We defined the primary exposure as PUFA desaturase activity, proxied by rs174546 at the FADS locus. Secondary exposures were defined as omega 3 and omega 6 PUFAs that could be proxied by genetic polymorphisms outside the FADS region. Our study used summary genetic data on 10 PUFAs and 67 cancers, corresponding to 562,871 cases and 1,619,465 controls, collected by the Fatty Acids in Cancer Mendelian Randomization Collaboration. We estimated odds ratios (ORs) for cancer per standard deviation increase in genetically proxied PUFA exposures. Findings: Genetically elevated PUFA desaturase activity was associated (P < 0.0007) with higher risk (OR [95% confidence interval]) of colorectal cancer (1.09 [1.07–1.11]), esophageal squamous cell carcinoma (1.16 [1.06–1.26]), lung cancer (1.06 [1.03–1.08]) and basal cell carcinoma (1.05 [1.02–1.07]). There was little evidence for associations with reproductive cancers (OR = 1.00 [95% CI: 0.99–1.01]; Pheterogeneity = 0.25), urinary system cancers (1.03 [0.99–1.06], Pheterogeneity = 0.51), nervous system cancers (0.99 [0.95–1.03], Pheterogeneity = 0.92) or blood cancers (1.01 [0.98–1.04], Pheterogeneity = 0.09). Findings for colorectal cancer and esophageal squamous cell carcinoma remained compatible with causality in sensitivity analyses for violations of assumptions. Secondary MR analyses highlighted higher omega 6 PUFAs (arachidonic acid, gamma-linolenic acid and dihomo-gamma-linolenic acid) as potential mediators. PUFA biosynthesis is known to interact with aspirin, which increases risk of bleeding and inflammatory bowel disease. In a phenome-wide MR study of non-neoplastic diseases, we found that genetic lowering of PUFA desaturase activity, mimicking a hypothetical ...
    Keywords Mendelian randomization ; Cancer risk ; Polyunsaturated fatty acids ; Omega 3 ; Omega 6 ; Delta-5 desaturase ; Medicine ; R ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2023-05-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: RAD51B in Familial Breast Cancer.

    Liisa M Pelttari / Sofia Khan / Mikko Vuorela / Johanna I Kiiski / Sara Vilske / Viivi Nevanlinna / Salla Ranta / Johanna Schleutker / Robert Winqvist / Anne Kallioniemi / Thilo Dörk / Natalia V Bogdanova / Jonine Figueroa / Paul D P Pharoah / Marjanka K Schmidt / Alison M Dunning / Montserrat García-Closas / Manjeet K Bolla / Joe Dennis /
    Kyriaki Michailidou / Qin Wang / John L Hopper / Melissa C Southey / Efraim H Rosenberg / Peter A Fasching / Matthias W Beckmann / Julian Peto / Isabel Dos-Santos-Silva / Elinor J Sawyer / Ian Tomlinson / Barbara Burwinkel / Harald Surowy / Pascal Guénel / Thérèse Truong / Stig E Bojesen / Børge G Nordestgaard / Javier Benitez / Anna González-Neira / Susan L Neuhausen / Hoda Anton-Culver / Hermann Brenner / Volker Arndt / Alfons Meindl / Rita K Schmutzler / Hiltrud Brauch / Thomas Brüning / Annika Lindblom / Sara Margolin / Arto Mannermaa / Jaana M Hartikainen

    PLoS ONE, Vol 11, Iss 5, p e

    2016  Volume 0153788

    Abstract: Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study was to investigate the role of ... ...

    Abstract Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study was to investigate the role of RAD51B variants in breast cancer predisposition, particularly in the context of familial breast cancer in Finland. We sequenced the coding region of RAD51B in 168 Finnish breast cancer patients from the Helsinki region for identification of possible recurrent founder mutations. In addition, we studied the known rs999737, rs2588809, and rs1314913 SNPs and RAD51B haplotypes in 44,791 breast cancer cases and 43,583 controls from 40 studies participating in the Breast Cancer Association Consortium (BCAC) that were genotyped on a custom chip (iCOGS). We identified one putatively pathogenic missense mutation c.541C>T among the Finnish cancer patients and subsequently genotyped the mutation in additional breast cancer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No significant association with breast cancer risk was seen in the meta-analysis of the Finnish datasets or in the large BCAC dataset. The association with previously identified risk variants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases and also among familial cases in the BCAC dataset. The most significant association was observed for the haplotype carrying the risk-alleles of all the three SNPs both among all cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11-1.19, P = 8.88 x 10-16) and among familial cases (OR: 1.24, 95% CI: 1.16-1.32, P = 6.19 x 10-11), compared to the haplotype with the respective protective alleles. Our results suggest that loss-of-function mutations in RAD51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.
    Keywords Medicine ; R ; Science ; Q
    Subject code 616 ; 610
    Language English
    Publishing date 2016-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus.

    Hisani N Horne / Charles C Chung / Han Zhang / Kai Yu / Ludmila Prokunina-Olsson / Kyriaki Michailidou / Manjeet K Bolla / Qin Wang / Joe Dennis / John L Hopper / Melissa C Southey / Marjanka K Schmidt / Annegien Broeks / Kenneth Muir / Artitaya Lophatananon / Peter A Fasching / Matthias W Beckmann / Olivia Fletcher / Nichola Johnson /
    Elinor J Sawyer / Ian Tomlinson / Barbara Burwinkel / Frederik Marme / Pascal Guénel / Thérèse Truong / Stig E Bojesen / Henrik Flyger / Javier Benitez / Anna González-Neira / Hoda Anton-Culver / Susan L Neuhausen / Hermann Brenner / Volker Arndt / Alfons Meindl / Rita K Schmutzler / Hiltrud Brauch / Ute Hamann / Heli Nevanlinna / Sofia Khan / Keitaro Matsuo / Hiroji Iwata / Thilo Dörk / Natalia V Bogdanova / Annika Lindblom / Sara Margolin / Arto Mannermaa / Veli-Matti Kosma / Georgia Chenevix-Trench / kConFab/AOCS Investigators / Anna H Wu

    PLoS ONE, Vol 11, Iss 8, p e

    2016  Volume 0160316

    Abstract: The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, we genotyped 92 SNPs in a ... ...

    Abstract The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, we genotyped 92 SNPs in a 900kb region (120,505,799-121,481,132) flanking rs11249433 in 45,276 breast cancer cases and 48,998 controls of European, Asian and African ancestry from 50 studies in the Breast Cancer Association Consortium. Genotyping was done using iCOGS, a custom-built array. Due to the complicated nature of the region on chr1p11.2: 120,300,000-120,505,798, that lies near the centromere and contains seven duplicated genomic segments, we restricted analyses to 429 SNPs excluding the duplicated regions (42 genotyped and 387 imputed). Per-allelic associations with breast cancer risk were estimated using logistic regression models adjusting for study and ancestry-specific principal components. The strongest association observed was with the original identified index SNP rs11249433 (minor allele frequency (MAF) 0.402; per-allele odds ratio (OR) = 1.10, 95% confidence interval (CI) 1.08-1.13, P = 1.49 x 10-21). The association for rs11249433 was limited to ER-positive breast cancers (test for heterogeneity P≤8.41 x 10-5). Additional analyses by other tumor characteristics showed stronger associations with moderately/well differentiated tumors and tumors of lobular histology. Although no significant eQTL associations were observed, in silico analyses showed that rs11249433 was located in a region that is likely a weak enhancer/promoter. Fine-mapping analysis of the 1p11.2 breast cancer susceptibility locus confirms this region to be limited to risk to cancers that are ER-positive.
    Keywords Medicine ; R ; Science ; Q
    Subject code 616
    Language English
    Publishing date 2016-01-01T00:00:00Z
    Publisher Public Library of Science (PLoS)
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top